The market for gene therapy in the treatment space is booming. Gene therapy products are sitting at a critical juncture: from technological pipedream to the centrepiece of clinical treatment.
The processed X-ray diffraction data used to produce the structures of SARS-Cov-2 proteins are freely available. This means that anyone can improve these models using open source software. Better structures mean more biological insights.
Like many scientific communities, structural biologists have responded extraordinarily quickly in the fight against the coronavirus (SARS-CoV-2, also referred to as 2019-nCoV) and the resultant disease COVID-19, by determining the structure of many of the viral proteins.